NasdaqGS:INBXBiotechs
How Investors May Respond To Inhibrx Biosciences (INBX) Ozekibart Colorectal Data And FDA Filing Moves
Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing ozekibart plus FOLFIRI produced higher response and disease control rates in heavily pretreated metastatic colorectal cancer, alongside a Biologics License Application submission for ozekibart in conventional chondrosarcoma and plans for FDA discussions on potential accelerated pathways.
Ozekibart’s profile as a precision-engineered DR5 agonist with signals of durable disease control across multiple hard-to-treat...